News summary

D&D Pharmatech’s liver drug resolves MASH in 62.5% of patients

Source: Longevity Technology • Published: 20 Nov 2026, 15:17

Summarized by Masters of Longevity from Longevity Technology.

A GLP-1–based peptide achieved histologic MASH resolution in a treated cohort.

D&D Pharmatech’s liver drug resolves MASH in 62.5% of patients
Key Takeaways
  • Zabopegdutide produced histologic resolution of MASH in 62.5% of patients.
  • The 48-week outcomes were assessed by liver biopsy as the endpoint.
  • Findings are from a clinical trial and are not proof of causality.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.